The WHO-UMC causality assessment is a standardized scheme for classifying the plausibility of the relationship between a medicinal product and an observed event in an individual case. The Uppsala Monitoring Centre assigns case reports to six categories: certain, probable/likely, possible, unlikely, conditional/unclassified, and unassessable/unclassifiable. The scheme structures a clinical-pharmacological assessment but does not provide mathematical proof of cause and effect.
Six Categories for the Individual Case
The ‘certain’ category requires, among other things, a plausible temporal relationship to drug intake, no convincing alternative explanation due to illness or other medicinal products, and a plausible course after discontinuation. The event must also be pharmacologically or phenomenologically unambiguous; a positive re-exposure is required if necessary. These high demands explain why a definitive classification in individual case reports is rare.
‘Probable/likely’ describes an appropriate temporal relationship where illness or other medicinal products are unlikely causes, and the course after discontinuation is clinically comprehensible. Re-exposure is not necessary for this category. For ‘possible’, the temporal relationship is also acceptable, but illness or other medicinal products could equally explain the observation; information on discontinuation may be missing or unclear.
‘Unlikely’ includes cases where the temporal distance makes the relationship improbable but not impossible, and plausible alternative explanations exist. ‘Conditional/unclassified’ is used when further data are needed or are still being reviewed. ‘Unassessable/unclassifiable’ denotes reports with insufficient or contradictory information that cannot be supplemented or verified.
Assessment Principles and Documented Consideration
The WHO-UMC system considers the clinical-pharmacological aspects of the patient’s history as well as the quality of the observation documentation. For classification, therefore, the temporal course, dose relationship, known pharmacological effects, dechallenge, rechallenge, competing diagnoses, concomitant medication, and objective findings are used, insofar as these are available in the case. Not every criterion is available in every report.
An assessment must not replace missing data with certainty. If crucial information is still pending, ‘conditional/unclassified’ precisely reflects this status. If it cannot be obtained even through follow-up or if it is contradictory, ‘unassessable/unclassifiable’ may be the appropriate conclusion. The category then documents a limit of the case information and not a statement that no relationship exists.
For cases from studies and other organized data collections, ICH E2D requires a reasoned medical assessment of the possible relationship. The WHO-UMC scheme can provide a comprehensible thought structure for this. However, it does not replace medical professional responsibility nor the assessment rules defined in a protocol, by an authority, or in a safety plan.
Distinction: Classification instead of Proof of Causality
The WHO-UMC assessment classifies a case; it does not prove a causal relationship. The Uppsala Monitoring Centre points out that the procedure was not developed as a precise and reliable quantitative estimate of the probability of a relationship. Different assessors may arrive at divergent judgments with incomplete information despite using the same categories.
The scheme reduces disagreement by providing general arguments for selecting a category. However, it does not transform statistical uncertainty, missing confounding data, or a rare clinical observation into certainty. For signals and aggregated data, other sources of evidence such as case series, exposure data, studies, or epidemiological comparisons also have independent significance.
The glossary term ‘bias’ concerns systematic distortions in data or studies, while ‘hazard ratio’ is a relative measure from comparative analyses. Both concepts can influence the assessment of a safety risk but are not categories for assessing an individual case report. The WHO-UMC causality assessment specifically focuses on the medical plausibility of a concrete patient case.
Relevance for clinical trials
In a study, the causality assessment must be aligned with the available clinical information, such as time of administration, dose changes, laboratory findings, discontinuation, re-initiation, and differential diagnoses. A blanket assignment without a case narrative later complicates the assessment of serious events and the classification of requested reports. Investigator assessments, sponsor assessments, and subsequently submitted findings should therefore be recorded with their respective timing and justification.
Full-service CROs like Mediconomics support WHO-UMC-oriented case assessment through structured medical review processes, targeted follow-up questions regarding alternative causes, and documentation of the reasons for the chosen category. Medical Safety and Medical Writing can also ensure that clinical narratives, database fields, and the assessment in the safety report reflect the same case logic.
Frequently Asked Questions (FAQ)
Does the ‘certain’ category legally establish a medicinal product as the cause?
No. ‘Certain’ is the strictest category of the scheme and requires a particularly convincing case constellation. It is a structured medical categorization, not a legally binding or statistical proof of causality.
When is ‘conditional/unclassified’ appropriate?
This category is appropriate when a report appears fundamentally assessable, but crucial data are still missing or additional information is currently being reviewed. It makes the provisional nature transparent.
Why is re-exposure not required for ‘probable/likely’?
For ‘probable/likely’, an appropriate temporal relationship, lack of probable alternative explanations, and a clinically plausible course after discontinuation are sufficient. Re-exposure is only required for ‘certain’ cases, if applicable, according to WHO-UMC criteria.
Regulatory References
- WHO-UMC, The use of the UMC system for standardised case causality assessment – defines the categories and criteria of the system.
- ICH E2D, Post-Approval Safety Data Management – requires an appropriate causality assessment for requested reports.
- GVP Module VI, Management and reporting of adverse reaction reports – addresses the medical assessment of individual safety cases.
- GVP Module VII, Periodic Safety Update Report – classifies the benefit of individual case assessments in safety analysis.